Dornase alfa showed no clear difference in mean absolute change in FEV1 (L) at 3 months compared with dornase alfa and mannitol (low certainty).
Dornase alfa showed no clear difference in mean absolute change in FVC (L) at 3 months compared with dornase alfa and mannitol (low certainty).
Dornase alfa may leads to higher change in quality of life ‐ CFQ‐R at 3 months compared with dornase alfa and mannitol (low certainty).
Dornase alfa showed no clear difference in number of people experiencing exacerbations at 3 months compared with dornase alfa and mannitol (low certainty).
Dornase alfa leads to higher relative mean percentage change in FVC (% predicted) at 6 months compared with placebo or no dornase alfa treatment (high certainty).
Dornase alfa showed no clear difference in change in quality of life ‐ CFQ‐R respiratory at 1 month compared with placebo or no dornase alfa treatment (low certainty).
Dornase alfa probably leads to lower number of people experiencing exacerbations at up to 2 years compared with placebo or no dornase alfa treatment (moderate certainty).
Dornase alfa may leads to higher mean relative percentage in FEV1 (L) at 3 months compared with hypertonic saline (low certainty).
Dornase alfa showed no clear difference in mean relative percentage in FVC (L) at 3 months compared with hypertonic saline (low certainty).
Dornase alfa showed no clear difference in mean relative percentage in quality of life score at 3 months compared with hypertonic saline (low certainty).
Dornase alfa showed no clear difference in mean absolute change in FEV1 (L) at 3 months compared with mannitol (low certainty).
Dornase alfa showed no clear difference in mean absolute change in FVC (L) at 3 months compared with mannitol (low certainty).
Dornase alfa may leads to higher change in quality of life ‐ CFQ‐R at 3 months compared with mannitol (low certainty).
Dornase alfa showed no clear difference in number of people experiencing exacerbations ‐ at 3 months compared with mannitol (low certainty).
Dornase alfa daily showed no clear difference in mean relative percentage in quality of life score at 3 months compared with alternate days (low certainty).
Dornase alfa daily showed no clear difference in mean relative percentage change in FEV1 (L) at 3 months compared with alternate days (low certainty).